Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R.

Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.

2.

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.

Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M.

Sci Transl Med. 2013 Mar 20;5(177):177ra38. doi: 10.1126/scitranslmed.3005930.

3.

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M.

Blood. 2011 Nov 3;118(18):4817-28. doi: 10.1182/blood-2011-04-348540. Epub 2011 Aug 17.

4.

Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.

Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, Yeh R, Capacio V, Olszewska M, Hosey J, Sadelain M, Brentjens RJ, Rivière I.

J Immunother. 2009 Feb-Mar;32(2):169-80. doi: 10.1097/CJI.0b013e318194a6e8.

5.

Production of clinical-grade plasmid DNA for human Phase I clinical trials and large animal clinical studies.

Przybylowski M, Bartido S, Borquez-Ojeda O, Sadelain M, Rivière I.

Vaccine. 2007 Jun 28;25(27):5013-24. Epub 2007 May 11.

PMID:
17537555
6.

Hydrogen peroxide generated extracellularly by receptor-ligand interaction facilitates cell signaling.

DeYulia GJ Jr, Cárcamo JM, Bórquez-Ojeda O, Shelton CC, Golde DW.

Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5044-9. Epub 2005 Mar 28.

7.

Vitamin C is a kinase inhibitor: dehydroascorbic acid inhibits IkappaBalpha kinase beta.

Cárcamo JM, Pedraza A, Bórquez-Ojeda O, Zhang B, Sanchez R, Golde DW.

Mol Cell Biol. 2004 Aug;24(15):6645-52.

8.

The laminin receptor modulates granulocyte-macrophage colony-stimulating factor receptor complex formation and modulates its signaling.

Chen J, Cárcamo JM, Bórquez-Ojeda O, Erdjument-Bromage H, Tempst P, Golde DW.

Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14000-5. Epub 2003 Nov 12.

9.

Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation.

Cárcamo JM, Pedraza A, Bórquez-Ojeda O, Golde DW.

Biochemistry. 2002 Oct 29;41(43):12995-3002.

PMID:
12390026
10.

Vitamin C inhibits granulocyte macrophage-colony-stimulating factor-induced signaling pathways.

Cárcamo JM, Bórquez-Ojeda O, Golde DW.

Blood. 2002 May 1;99(9):3205-12.

11.

Increased uptake and accumulation of vitamin C in human immunodeficiency virus 1-infected hematopoietic cell lines.

Rivas CI, Vera JC, Guaiquil VH, Velásquez FV, Bórquez-Ojeda OA, Cárcamo JG, Concha II, Golde DW.

J Biol Chem. 1997 Feb 28;272(9):5814-20.

Supplemental Content

Loading ...
Support Center